Large Joint Replacement Market: Set For A Rebound?

Beaten down by the great recession, the large joint arthroplasty market appears to be on the cusp of a turnaround, with several big players reporting encouraging Q4 and full-year 2012 results. A full recovery in this space is likely to take some time, but technology advances could help jumpstart the process, and there may be some interesting dynamics ahead in the patient-specific implant and robotic ortho device arenas.

The hip and knee reconstruction market was especially hard-hit by the economic downturn of the past several years, as US patients, many of whom lost their jobs and/or insurance, postponed needed joint replacement surgery, and European markets, hit with bruising austerity measures, also came under pressure. The one bright spot was in emerging market countries (particularly China, India, and Brazil), which posted high single-digit or low double-digit growth in hip and knee implant sales revenues, albeit off a smaller base, as the US and European markets sputtered. Growth prospects going forward are expected to continue to be strongest in the emerging markets; however, slow but steady improvements in the global economy could help set the stage for a rebound in this market in the US and Europe beginning this year and accelerating in 2014, driven by pent-up procedural demand and favorable underlying demographics.

Indeed, there have been encouraging signs already suggesting the US joint reconstruction market may be on the mend, with Depuy Synthes/Johnson & Johnson (J&J), Stryker Corp., and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.